© 2024
© 2024
Accelerate your discovery stage research by leveraging our team of experts to help with your custom bioconjugation project. Whether you are looking to assemble antibody-drug conjugates (ADCs), pegylated proteins, siRNA conjugates, vaccine conjugates or surface activation, we have the tools and experience to deliver.
Bioconjugates are a growing class of biopharmaceuticals that are developed by attaching two molecules together, of which at least one is a biomolecule. However the discovery phase can be time consuming and requires specialist expertise. Genie Biotech can act as your partner to accelerate the development of your novel bioconjugate.
Antibody Conjugates represent a significant area of clinical and economic growth for the biopharmaceutical market. Antibody Drug Conjugates (ADCs) combine the targeted specificity of a monoclonal antibody with a cytotoxic small molecule and are manufactured by linking these monoclonal antibodies to the highly toxic small molecules. There are hundreds of ADC candidates in development and analysts expect the market for these drugs to continue to expand. Production and analysis of varying quantities of ADC candidates is required to support research and process development. Genie Biotech has an integrated platform of products and services to support ADC development from molecule inception through scale-up.
Accelerate and de-risk your ADC development with our expertise in payloads, linkers, and SAR generation.
We create custom antibody-drug conjugates (ADCs) and related bioconjugates to meet your specific needs.
We provide comprehensive analysis of ADC drug loading, conjugation sites, purity, and aggregation profiles.
Validate your ADC with expert functional testing, including bioassays for potency, efficacy, and safety across various modalities.
Monomeric antigens can be poorly immunogenic, and its multimerisation can confer single shot seroconversion and better Ab responses, due to improved drainage to lypmh nodes and certain VLPs packaging TLR adjuvants. Furthermore oriented antigen display can produce better quantitative and qualitative Abs than random display.
Use our technology to orient the display of any antigen or agonist of choice onto a nanoparticle for improved outcome. Our technology is simple, fast and robust, accelerating the research and development pipeline of your Prophylactic or Therapeutic Vaccine strategies
Traditional antibody labelling technologies usually take advantage of the multiple Lys groups located in the antibody. Modification of the Lys groups changes the overall pI of the antibody and leads to higher nonspecific binding. In addition, if some of the modified or conjugated Lys residues are located on the antigen binding sites this method may produce partially active or inactive antibody conjugates that may not bind to the antigen.
With our extensive expertise in bioconjugation techniques we deliver site- specific conjugation solutions to decrease the amount of material used, reduce detection thresholds and ultimately lower the cost of diagnostic application.
Together we can design and develop the optimal conjugation strategy, carry out proof of concept, pilot run and method transfer.
Genie Biotech’s scientists have extensive experience in developing fluorescent-, antibody-, peptide-, and oligonucleotide-based detection agents. We provide a complete solution for the development of your diagnostic bioconjugate, including:
Enzyme conjugates
Horseradish peroxidase (HRP)
Surface/Matrix bioconjugates:
Covalently coupled antibody-surface conjugates
Biotin conjugates:
Biotin/Streptavidin-labelled proteins
Magnetic and nonmagnetic bead conjugates:
Magnetic bead conjugates
Latex bead conjugates
Gold nanoparticles
Sustained Delivery prolongs the release of a therapeutic which can result in increased exposure and potency of a given target molecule. Advances in the design of biomaterials, such as hydrogels, microspheres, implants and nanoparticles, have contributed to the precise delivery of this therapeutic modality revolutionizing how patients are treated for many acute and chronic conditions.
Genie Biotech’s proprietary conjugation technology allows Researchers to fine tune a drug’s release in a highly controlled, novel manner. Not only are target molecules site-specifically bound to a matrix of your choosing, but the conjugate bond can also be tuned to reverse thus releasing the native molecule.
Target molecules can be rapidly installed on a selected matrix under mild conditions, preserving the biological function of your therapeutic.
You can then fine tune the reversibility by controlling the rate at which the conjugate bond hydrolyzes to release your native biologic from the matrix.
Accelerate your discovery stage research by leveraging our team of experts to help with your custom bioconjugation project. Whether you are looking to assemble antibody-drug conjugates (ADCs), pegylated proteins, siRNA conjugates, vaccine conjugates or surface activation, we have the tools and experience to deliver.
Bioconjugates are a growing class of biopharmaceuticals that are developed by attaching two molecules together, of which at least one is a biomolecule. However the discovery phase can be time consuming and requires specialist expertise. Genie Biotech can act as your partner to accelerate the development of your novel bioconjugate.
Antibody Conjugates represent a significant area of clinical and economic growth for the biopharmaceutical market. Antibody Drug Conjugates (ADCs) combine the targeted specificity of a monoclonal antibody with a cytotoxic small molecule and are manufactured by linking these monoclonal antibodies to the highly toxic small molecules. There are hundreds of ADC candidates in development and analysts expect the market for these drugs to continue to expand. Production and analysis of varying quantities of ADC candidates is required to support research and process development. Genie Biotech has an integrated platform of products and services to support ADC development from molecule inception through scale-up.
Test your discovery-stage ADC further with functional testing, such as cell-based assays and receptor binding. Our experts develop bioassays for assessment of potency, efficacy and safety, giving you the benefit of our experience across a diverse range of modalities. To help understand your molecule in detail our assays include luminescence, fluorescence, absorbance plate-based assays, Flow cytometry, live cell imaging and Cytokine analysis.
Monomeric antigens can be poorly immunogenic, and its multimerisation can confer single shot seroconversion and better Ab responses, due to improved drainage to lypmh nodes and certain VLPs packaging TLR adjuvants. Furthermore oriented antigen display can produce better quantitative and qualitative Abs than random display.
Use our technology to orient the display of any antigen or agonist of choice onto a nanoparticle for improved outcome. Our technology is simple, fast and robust, accelerating the research and development pipeline of your Prophylactic or Therapeutic Vaccine strategies
Traditional antibody labelling technologies usually take advantage of the multiple Lys groups located in the antibody. Modification of the Lys groups changes the overall pI of the antibody and leads to higher nonspecific binding. In addition, if some of the modified or conjugated Lys residues are located on the antigen binding sites this method may produce partially active or inactive antibody conjugates that may not bind to the antigen.
With our extensive expertise in bioconjugation techniques we deliver site- specific conjugation solutions to decrease the amount of material used, reduce detection thresholds and ultimately lower the cost of diagnostic application.
Together we can design and develop the optimal conjugation strategy, carry out proof of concept, pilot run and method transfer.
Genie Biotech’s scientists have extensive experience in developing fluorescent-, antibody-, peptide-, and oligonucleotide-based detection agents. We provide a complete solution for the development of your diagnostic bioconjugate, including:
Enzyme conjugates
Horseradish peroxidase (HRP)
Surface/Matrix bioconjugates:
Covalently coupled antibody-surface conjugates
Biotin-/Streptavidin conjugates:
Biotin-labeled proteins/haptens
Streptavidin-labeled proteins/aptens
Paramagnetic and nonmagnetic beads and particle conjugates:
Magnetic beads – antigen/antibody conjugates
Latex beads – antigen/antibody conjugates
Gold nanoparticles
Sustained Delivery prolongs the release of a therapeutic which can result in increased exposure and potency of a given target molecule. Advances in the design of biomaterials, such as hydrogels, microspheres, implants and nanoparticles, have contributed to the precise delivery of this therapeutic modality revolutionizing how patients are treated for many acute and chronic conditions.
Genie Biotech’s proprietary conjugation technology allows Researchers to fine tune a drug’s release in a highly controlled, novel manner. Not only are target molecules site-specifically bound to a matrix of your choosing, but the conjugate bond can also be tuned to reverse thus releasing the native molecule.
Target molecules can be rapidly installed on a selected matrix under mild conditions, preserving the biological function of your therapeutic.
Test your discovery-stage ADC further with functional testing, such as cell-based assays and receptor binding. Our experts develop bioassays for assessment of potency, efficacy and safety, giving you the benefit of our experience across a diverse range of modalities. To help understand your molecule in detail our assays include luminescence, fluorescence, absorbance plate-based assays, Flow cytometry, live cell imaging and Cytokine analysis.
Determination of drug loading (DAR), Analysis of conjugation site, Analysis of ADC homogeneity, Chromatographic and spectroscopic purity, Quantification of residual unconjugated drug and Aggregation profile
We design and deliver tailored solutions using our conjugation chemistries, assembling a variety antibody-drug conjugates (ADC), antibody fragment-drug conjugates (ScFvDC), antibody-oligonucleotide conjugates (AOC, Bispecific Antibodies (bsAbs) and other protein- and peptide-drug conjugates.
Leverage our experience in the synthesis of payloads, linkers, and payload-linker chemical to enable the rapid generation of structure activity relationships (SAR) of various linker combinations with your new payloads. Accelerating and de-risking the development and manufacture of your next-generation therapies, Our integrated approach supports the lifecycle of ADC discovery and development.
We design and deliver tailored solutions using our conjugation
chemistries, assembling a variety antibody-drug conjugates (ADC),
antibody fragment-drug conjugates (ScFvDC), antibody-oligonucleotide
conjugates (AOC, Bispecific Antibodies (bsAbs) and other protein- and
peptide-drug conjugates
Linker payload design & synthesis
We design and deliver tailored solutions using our antibody-oligonucleotide
conjugates (AOC, Bispecific Antibodies (bsAbs) and other protein- and
peptide-drug conjugates.
We design and deliver tailored solutions using our conjugation
chemistries, assembling a variety antibody-drug conjugates (ADC),
antibody fragment-drug conjugates (ScFvDC), antibody-oligonucleotide
conjugates (AOC, Bispecific Antibodies (bsAbs) and other protein- and
peptide-drug conjugates
Leverage our experience in the synthesis of payloads. . .
Genie Biotech will perform a structural assessment using our suite of chromatographic, Mass Spectrometric and Biophyscial instrumentation to confirm the viability of your new bioconjugate before returning it to you.
Genie Biotech will either receive your candidate(s) of interest or synthesize it and begin the work of assembling your conjugate of choice. In combination with our high throughput approach, and unique sitespecific chemistries we can quickly identify the most promising candidates for stability and scalability.
As an extension of your team, we would develop a strategy tailored to your specific product, proposing the experimental matrix, deliverables, expected timelines and even exploring the IP landscape.
Leave the assembling to us
Whether you are looking to make a custom purification column or a specific ADC, leverage our dedicated team to assemble and test your desired product.
Mammalian and Bacterial Expression systems
Genie Biotech can offer recombinant protein production services from our in-house BSL-2 facility.
Structural Characterisation
Using our suite of Chromatographic, Mass Spectrometric and Biophysical instruments we have the capability to monitor, asses and qualify your conjugates
Site-specific chemistries,
payloads & ready-made
conjugates
Explore our bioconjugation toolbox and Purchase off-the-shelf products developed for your early stage research.